Abstract
Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Current Pharmaceutical Design
Title:Pharmacogenomics of Oral Antithrombotic Drugs
Volume: 22 Issue: 13
Author(s): Flavia Storelli, Youssef Daali, Jules Desmeules, Jean-Luc Reny and Pierre Fontana
Affiliation:
Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology
Abstract: Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.
Export Options
About this article
Cite this article as:
Storelli Flavia, Daali Youssef, Desmeules Jules, Reny Jean-Luc and Fontana Pierre, Pharmacogenomics of Oral Antithrombotic Drugs, Current Pharmaceutical Design 2016; 22 (13) . https://dx.doi.org/10.2174/1381612822666151208122845
DOI https://dx.doi.org/10.2174/1381612822666151208122845 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Vascular Effects of Antiarrhythmic Drugs and the Roles of K+ Channels
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design MicroRNAs Patents: The Road From Bench to Bedsides for Cancer Treatment
Recent Patents on DNA & Gene Sequences Pattern of Medication Use Among Older Inpatients in Seven Hospitals in Italy: Results from the Criteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project
Current Drug Safety Platelet Turnover in Atherothrombotic Disease
Current Pharmaceutical Design AMP-Activated Protein Kinase: Structure and Regulation
Current Protein & Peptide Science Quantification and Pharmacokinetics Study of Pedunculoside in Rats by Using UPLC-MS/MS
Current Pharmaceutical Analysis Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Medicinal Agents in the Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Strategies for Effective Naked-DNA Vaccination Against Infectious Diseases
Recent Patents on Anti-Infective Drug Discovery Prevention of Postprandial Metabolic Stress in Humans: Role of Fruit- Derived Products
Endocrine, Metabolic & Immune Disorders - Drug Targets Catecholamines, Sympathetic Innervation and Immunity: Role in Experimental and Rheumatoid Arthritis
Letters in Drug Design & Discovery Sesbania: A Prospective Candidate to be Excavated for Anticancer Drugs
The Natural Products Journal Editorial [Hot Topic:The Metabolic Treatment of Coronary Artery Disease and Heart Failure(Executive Editor: Pericle Di Napoli)]
Current Pharmaceutical Design Microparticles: A Pivotal Nexus in Vascular Homeostasis and Disease
Current Clinical Pharmacology Current Therapeutic Approaches in Inflammatory Bowel Disease
Current Pharmaceutical Design Diamidine Activity Against Trypanosomes: The State of the Art
Current Molecular Pharmacology